BioSpace News Archive

Gossamer Bio, Inc. today announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).

Entact Bio today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developing enhancement-targeting chimeric (ENTAC™) molecules.

BiondVax Pharmaceuticals Ltd. today announced that Professor Dr. med. Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).

Researchers at University College London (UCL) published the results of the first study to find that short-term air pollution exposure is associated with acutely increased depression symptoms in people with bipolar disorder.

Click Therapeutics, Inc. today announced their partnership with The Massachusetts Medical Society (“MMS”), a statewide professional association for physicians and medical students, supporting more than 25,000 members.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases.

TrueBinding Inc highlighted the unique method of action (MOA) of TB006, an investigational monoclonal antibody against Galectin-3 (Gal-3) for the treatment of mild to severe AD, at the recent 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.

HTG Molecular Diagnostics, Inc. announced there will be at least eight scientific abstracts featuring HTG’s proprietary HTG EdgeSeq™ technology presented at the 45th Annual San Antonio Breast Cancer Symposium and at the 64th Annual American Society of Hematology Annual Meeting.

AbbVie and HotSpot Therapeutics, Inc. today announced an exclusive worldwide collaboration and option to license agreement for HotSpot’s discovery-stage IRF5 program for the treatment of autoimmune diseases.

Corza Medical announced that it has appointed Tom Testa to the role of Chief Executive Officer and member of the Board of Directors.